$236.80 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter

Brokerages forecast that Horizon Pharma PLC (NASDAQ:HZNP) will report sales of $236.80 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Horizon Pharma’s earnings. The lowest sales estimate is $230.27 million and the highest is $247.63 million. Horizon Pharma reported sales of $223.88 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.8%. The firm is expected to issue its next quarterly earnings results before the market opens on Wednesday, May 8th.

According to Zacks, analysts expect that Horizon Pharma will report full year sales of $1.24 billion for the current year, with estimates ranging from $1.24 billion to $1.25 billion. For the next financial year, analysts expect that the business will report sales of $1.39 billion, with estimates ranging from $1.35 billion to $1.44 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.13. The company had revenue of $355.50 million during the quarter, compared to analysts’ expectations of $334.22 million. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. Horizon Pharma’s quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.29 EPS.

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald upped their price target on Horizon Pharma from $26.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Piper Jaffray Companies set a $33.00 target price on Horizon Pharma and gave the company a “buy” rating in a report on Thursday, April 4th. BMO Capital Markets increased their target price on Horizon Pharma to $29.00 and gave the company a “market perform” rating in a report on Thursday, April 4th. They noted that the move was a valuation call. Mizuho reissued a “hold” rating and set a $21.00 target price on shares of Horizon Pharma in a report on Thursday, February 7th. Finally, BidaskClub raised Horizon Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 5th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Horizon Pharma presently has an average rating of “Buy” and an average target price of $30.73.

NASDAQ HZNP traded down $0.38 during trading hours on Thursday, reaching $25.63. The company’s stock had a trading volume of 944,253 shares, compared to its average volume of 1,908,834. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of 14.01, a PEG ratio of 1.48 and a beta of 1.15. Horizon Pharma has a 1-year low of $12.55 and a 1-year high of $29.44. The company has a current ratio of 2.03, a quick ratio of 1.97 and a debt-to-equity ratio of 1.80.

In other news, EVP Geoffrey M. Curtis sold 8,835 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $23.15, for a total value of $204,530.25. Following the completion of the sale, the executive vice president now directly owns 32,202 shares in the company, valued at $745,476.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Geoffrey M. Curtis sold 10,080 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $21.21, for a total value of $213,796.80. Following the completion of the sale, the executive vice president now owns 35,367 shares of the company’s stock, valued at $750,134.07. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Private Capital Group LLC grew its position in shares of Horizon Pharma by 141.5% in the fourth quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,150 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Horizon Pharma by 79.5% in the fourth quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 4,179 shares in the last quarter. Meeder Asset Management Inc. grew its position in shares of Horizon Pharma by 631.9% in the fourth quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 8,588 shares in the last quarter. D.A. Davidson & CO. grew its position in shares of Horizon Pharma by 5.1% in the fourth quarter. D.A. Davidson & CO. now owns 10,592 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 512 shares in the last quarter. Finally, Keybank National Association OH purchased a new stake in shares of Horizon Pharma in the fourth quarter valued at approximately $209,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Recommended Story: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.